180 Life Sciences

180 Life Sciences Pivots from Biotech to Ethereum Treasury Strategy with $581 Million in Funding

- 180 Life Sciences Corp. (Nasdaq: ATNF) has raised a total of $581 million through a $425 million private placement and $156 million convertible notes offering to execute an Ethereum treasury strategy. - The company plans to rebrand as ETHZilla Corporation and will use the proceeds primarily to purchase Ethereum (ETH) while maintaining its legacy biotech and iGaming operations. - Electric Capital will serve as external asset manager to implement a differentiated yield generation program designed to outperform traditional ETH staking through various DeFi strategies. - The financing was led by prominent crypto investors including Electric Capital, Polychain Capital, and notable Ethereum ecosystem founders, positioning the company as a public market vehicle for Ethereum exposure.